Presentation to highlight Autonomix’s catheter-based technology and key findings from lead-in patients in ongoing human clinical trial in pancreatic cancer…
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb.…
Media ReleaseCOPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong…
BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage…
Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug…
Ongoing Phase 1 study is funded by a foundation grant Daré received a royalty-free, exclusive license to the US patents…
OvaStem® Demonstrates Strong Long-Term Efficacy with No Safety Concerns, Backed by Pending Orphan Drug Designation for AlloStem®PHOENIX, Feb. 20, 2025…
SAN FRANCISCO and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor…
TUS+VEN+AZA triplet achieves complete responses (CRs) in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients, including a measurable residual disease (MRD)…